8 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
"Proposal to assess an innovative Immunotherapy, based on a thioredox peptide antigen, in a Phase I Trial for Type-1 Diabetes" (EXALT)
Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,
"Type-1 diabetes (T1D) is an autoimmune disease in which pancreatic β-cells are gradually destroyed by autoreactive T-cells recognising autoantigens (Auto-Ag) such as GAD65 and insulin. ImCyse, a small SME, has developed a new technology based on short synthetic peptides flanked with a thioredox motif, which silence the pathogenic immune response against several auto-Ag through activation of one a ...
Voir le projet
7
Participants partenaires
TERMINÉ
The development of a novel therapeutic vaccine for the selective treatment of the autoimmune disorder, Graves’ disease (DAVIAD)
Date du début: 1 déc. 2013, Date de fin: 30 nov. 2017,
This aim of the DAVIAD proposal is to develop a therapeutic vaccine for Graves’ disease (GD) that has a better safety and efficacy profile than current treatments. There is a high level of unmet need in the treatment of Graves’ disease especially in patients with Graves orbitopathy and children and adolescents (who generally suffer from the most chronic form of the disease). Autoimmune diseases ar ...
Voir le projet
5
Participants partenaires
TERMINÉ
Advanced Immunization Technologies (ADITEC)
Date du début: 1 oct. 2011, Date de fin: 30 sept. 2017,
Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and ...
Voir le projet
53
Participants partenaires
TERMINÉ
A Multi-Stage Malaria Vaccine (MultiMalVax)
Date du début: 1 oct. 2012, Date de fin: 31 mars 2017,
A highly effective malaria vaccine is a major goal of global health research and will likely require a multi-stage product. MultiMalVax will develop a highly effective multi-stage malaria vaccine to the point of proof-of-concept phase II testing in Europe, prior to trials in malaria-endemic areas.Remarkable recent advances in vaccine design for all four stages of the P. falciparum parasite’s life- ...
Voir le projet
6
Participants partenaires
TERMINÉ
Prevention of hepatitis C virus (HCV) and HIV-1 co-infections through induction of potent T cell responses using prime-boost viral vector vaccine regimens (PEACHI)
Date du début: 1 févr. 2013, Date de fin: 31 janv. 2017,
"The goal of the PEACHI project is to develop simple, affordable and effective vaccine strategies that can be given alone or in combination to prevent hepatitis C virus (HCV), human immunodeficiency virus type 1 (HIV-1) and co-infection. The vaccines are based on novel and powerful viral vectors for in vivo delivery of antigens.The PEACHI Consortium members have employed replication-defective simi ...
Voir le projet
5
Participants partenaires
TERMINÉ
UNIversal solutions in TElemedicine Deployment for European HEALTH care (United4Health)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2015,
United4Health aims to exploit and further deploy innovative telemedicine services implemented and trialled under the RENEWING HEALTH project. A limited number of interventions have been selected from the basket of those already validated or under validation in RENEWING HEALTH; they will be trialled in 14 regions to guarantee aggregation of data and comparability of results. All service solutions a ...
Voir le projet
33
Participants partenaires
TERMINÉ
Understanding how immunostimulant combinations in adjuvants synergise to enhance vaccine responses (ADJSYN)
Date du début: 1 juil. 2013, Date de fin: 30 juin 2015,
The need to develop vaccines against challenging diseases such as malaria or tuberculosis requires effective adjuvants to improve the immune responses against purified antigens, as these antigens often lack intrinsic immunogenicity. Most adjuvants act on innate immunity leading to the activation of antigen presenting cells and induction of memory T cell and antibody responses to the vaccine. Inclu ...
Voir le projet
2
Participants partenaires
TERMINÉ
Exploring the roles and plasticity of T-cell responses in anti-BACterial immunity (T-BAC)
Date du début: 1 mai 2013, Date de fin: 30 avr. 2015,
"Antibodies against bacterial polysaccharides and proteins play a role in anti-bacterial immunity. To date, S. aureus vaccine candidates were selected to induce functional antibody responses. However, a potential role for T-cell mediated immunity is emerging, supported by the fact that impaired Th17 responses in patients with hyper IgE syndrome are linked to abnormal susceptibility to S. aureus in ...
Voir le projet